MedTrace Logo

Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.

NCT05305508 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-02-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of CaD in reducing SARS-CoV-2 viral load in non-hospitalized adult patients diagnosed with COVID-19, documented with a positive SARS-CoV-2 PCR and with the occurrence of COVID-19 symptoms.

Conditions

  • COVID-19 Virus Disease

Interventions

DRUG

Calcium Dobesilate

The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.

DRUG

Mannitol

The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.

Sponsors & Collaborators

  • OM Pharma SA

    collaborator INDUSTRY

  • Hervé SPECHBACH

    lead OTHER

Principal Investigators

  • Hervé SPECHBACH, MD · HUG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-17
Primary Completion
2023-11-10
Completion
2024-02-05

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305508 on ClinicalTrials.gov